跳至主要内容
临床试验/NCT01535586
NCT01535586Unknown4 期

A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder

The VA Western New York Healthcare System0 个研究点目标入组 42 人开始时间: 2012年4月1日最近更新:
适应症

试验速览

阶段
4 期
发起方
入组人数
42
主要终点
Efficacy

研究概览

简要总结

Sleep disturbances are cardinal features of Veterans with post traumatic stress disorder (PTSD). In particular, obstructive sleep apnea is reported to occur more frequently in patients with PTSD compared to those without PTSD and contribute to worsening cognitive and behavioral functions. Continuous positive airway pressure (CPAP) is considered the treatment of choice for OSA but adherence to CPAP in Veterans with PTSD is poor compared to the general population. The proposed study aims at comparing the efficacy, tolerability, and adherence of mandibular advancing devices-an alternative therapy to OSA- to CPAP. The study is instrumental in identifying the optimal OSA therapy for Veterans with PTSD and the OSA phenotype that would predict MAD response.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • • Consecutive patients aged 18-70 years of age
  • Documented obstructive sleep apnea by polysomnography (AHI≥5 or more/hr)
  • Established diagnosis of PTSD related to any past lifetime traumatic event and have a diagnosis of current, chronic PTSD

排除标准

  • • Central sleep apnea defined as central apnea/hypopnea >50% of the total respiratory events
  • Prior treatment for sleep apnea
  • Veterans with fewer than 4 teeth remaining in either arch
  • Coexisting narcolepsy
  • Tempo-mandibular joint disease
  • Prominent suicidal or homicidal ideation
  • Diagnosis of dementia

结局指标

主要结局

Efficacy

时间窗: 12 weeks

The primary objective of this trial is to assess the efficacy of MAD versus CPAP in the treatment of OSA in Veterans with PTSD.Treatment will be considered efficacious (successful) when the apnea-hypopnea index is \< 5 in the absence of hypoxemia defined as SvO2\<90%.

次要结局

  • Adherence(12 weeks)

研究者

发起方
The VA Western New York Healthcare System
申办方类型
Fed
责任方
Principal Investigator
主要研究者

Mr. Shawn Gall

Administrative officer

The VA Western New York Healthcare System

相似试验